1. Home
  2. VAL vs BLCO Comparison

VAL vs BLCO Comparison

Compare VAL & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

HOLD

Current Price

$97.48

Market Cap

6.3B

Sector

Energy

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.67

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VAL
BLCO
Founded
1975
1853
Country
Bermuda
Canada
Employees
5642
N/A
Industry
Oil & Gas Production
Ophthalmic Goods
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
VAL
BLCO
Price
$97.48
$16.67
Analyst Decision
Hold
Buy
Analyst Count
5
12
Target Price
$63.50
$18.55
AVG Volume (30 Days)
1.2M
439.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,101,000,000.00
Revenue This Year
N/A
$8.61
Revenue Next Year
$15.62
$5.52
P/E Ratio
$16.22
N/A
Revenue Growth
N/A
6.47
52 Week Low
$27.15
$10.45
52 Week High
$102.20
$18.92

Technical Indicators

Market Signals
Indicator
VAL
BLCO
Relative Strength Index (RSI) 63.98 42.30
Support Level $45.71 $16.35
Resistance Level $102.20 $16.81
Average True Range (ATR) 4.00 0.50
MACD -1.02 -0.19
Stochastic Oscillator 88.96 22.40

Price Performance

Historical Comparison
VAL
BLCO

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: